AquaBeam
Waterjet robotic system for benign prostatic hyperplasia
The AquaBeam system is a unique and patented robotic device designed for the ablation and removal of prostate tissue in patients with lower urinary tract systems caused by benign prostatic hyperplasia (BPH).
Made by
ARE YOU A HEALTHCARE PROFESSIONAL?
The following content is intended for healthcare professionals as it concerns products categorised as medical devices that must be used or operated by professionals in the medical/healthcare sector.
N.B.: Pursuant to and for the purposes of Art. 76 of Italian Presidential Decree (DPR) 445/2000, aware of the liability and the civil and criminal repercussions for false declarations and/or for the preparation or use of false documents, as well as in the event of the production of documents containing information that no longer corresponds to the truth, I confirm that I am a HEALTHCARE PROFESSIONAL.
System operation
AquaBeam combines three principles of action:
- Real-time imaging. Intraprocedural ultrasound and cystoscopic guidance
- Robotic procedure. Planned and precise tissue removal performed robotically by dedicated software
- Waterjet. Heat-free waterjet ablation of target tissue
By simultaneously applying these three technologies, AquaBeam delivers fully robotic, targeted and personalised prostate tissue ablation adapted to each patient’s unique anatomy.
The procedure with AquaBeam
The procedure is fully automated and precise thanks to the combination of ultrasound imaging, cystoscopic vision, robotic technology and waterjet ablation. Once the correct ultrasound image has been identified, all the surgeon needs to do is plan the angles and contouring of treatment, identifying the viable structures to be preserved and the excess tissue to be removed. Once the treatment has been confirmed, AquaBeam delivers waterjet ablation of the tissue, following the doctor’s planning with millimetric precision. The operator can stop and amend the treatment plan at any time at his or her discretion.
Clinical benefits
-
Obstruction removal on a par with results obtained with other technologies.
-
Significant reduction in operating times.
-
Elimination of potential operator-dependent errors.
-
Significantly lower use of thermal energy.
-
Minor blood-related postoperative complications. Scientific research suggests
an average transfusion rate of 1.9% for all prostate sizes using aquablation. Other techniques, such as TURP, PVP or enucleation, show a transfusion rate as high as 7%. This is due to poor standardisation as the prostate size increases, resulting in longer operating times, as well as an increased risk of bleeding and perioperative complications in general.
Benefits for the patient
-
Heat-free treatment, for greater preservation of the prostatic anatomical structures not affected by ablation.
-
Robotic and targeted tissue removal. AquaBeam adapts to the patient’s anatomy to treat only the necessary tissue, eliminating the risk of a manual treatment that is either too aggressive or not sufficiently effective in terms of urethral obstruction removal.
-
High likelihood of maintaining ejaculatory function if the patient so wishes.
-
Reduced length of hospital stay – with fewer drugs required – and earlier resumption of normal daily activities.
23/04/2025
about care, who is speaking today? Prof. Morelli
Intervista al Prof. Girolamo Morelli, Urologo della Casa di cura S. Rossore di Pisa Un approfondimento sulla metodica Aquablation nel trattamento dell’Iperplasia Prostatica Benigna. Dalle differenze rispetto alle tecniche tradizionali, all’identikit del paziente ideale,...
- 2020 February
Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Urology. Peter Gilling et al. - 2020 April
Transfusion rates after 800 Aquablation procedures using various haemostasis methods. BJU International. Dean Elterman et al.
For more information write us
"*" indicates required fields
